Piper Sandler initiated coverage on Abbott Laboratories (NYSE:ABT) with an "overweight" rating and a price target of $131 per ...

Piper Sandler initiates coverage on Abbott with an Overweight rating, citing its diversified business model, strong medtech ...

Abbott ABT is facing a challenging business environment globally. Unfavorable foreign exchange impact continues to impede ...

Texas Governor Greg Abbott shakes hands with newly appointed Eighth Division Business Court Justice Jerry Bullard following ...

Let's not forget about Abbott Laboratories' impressive streak of 52 consecutive annual dividend increases, which also makes ...

Some people are facing delays in filling prescriptions for the glucose sensor. Abbott expects to resolve the problem soon.

Abbott's strong innovation pipeline, including advancements in CGM systems, supports its market share gains and growth ...

Adam Maeder, an analyst from Piper Sandler, has initiated a new Buy rating on Abbott Laboratories (ABT). Adam Maeder has given his Buy rating ...

Abbott Laboratories (ABT) stock saw a decline, ending the day at $114.88 which represents a decrease of $-3.25 or -2.75% from the prior close of $118.13. The stock opened at $117.5 and touched a low ...

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report), ...

Abbott Laboratories closed $4.01 short of its 52-week high ($121.64), which the company reached on March 8th.

Cardio.ai announced a collaboration with Abbott (NYSE:ABT) to develop AI applications for the medtech giant's imaging ...